230 related articles for article (PubMed ID: 29317233)
1. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Luo P; Wang X; Zhou J; Li L; Jing Z
Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
[TBL] [Abstract][Full Text] [Related]
2. High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas.
Ma J; Tian K; Du J; Wu Z; Wang L; Zhang J
J Neurosurg; 2019 Jan; 132(1):140-149. PubMed ID: 30641849
[TBL] [Abstract][Full Text] [Related]
3. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.
Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J
Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the BMP4/SMAD signaling pathway in skull base chordomas is associated with poor prognosis.
Feng Y; Zhang Q; Wang Z; Yan B; Wei W; Li P
Int J Clin Exp Pathol; 2015; 8(7):8268-75. PubMed ID: 26339396
[TBL] [Abstract][Full Text] [Related]
5. Chordoma: Immunohistochemical Analysis of Brachury.
Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN
Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431
[TBL] [Abstract][Full Text] [Related]
6. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
7. [Chordoma].
George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma.
Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y
World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781
[TBL] [Abstract][Full Text] [Related]
9. Chordoma of the skull base: predictors of tumor recurrence.
Pallini R; Maira G; Pierconti F; Falchetti ML; Alvino E; Cimino-Reale G; Fernandez E; D'Ambrosio E; Larocca LM
J Neurosurg; 2003 Apr; 98(4):812-22. PubMed ID: 12691407
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics, immunohistochemistry, and outcomes of 77 patients with skull base chordomas.
Ouyang T; Zhang N; Zhang Y; Jiao J; Ren J; Huang T; Chen J
World Neurosurg; 2014; 81(5-6):790-7. PubMed ID: 23298670
[TBL] [Abstract][Full Text] [Related]
11. Male sex as a risk factor for the clinical course of skull base chordomas.
Rachinger W; Eigenbrod S; Dützmann S; Simon M; Feigl GC; Kremenevskaja N; Kretzschmar H; Zausinger S; Kreth FW; Thon N; Tonn JC
J Neurosurg; 2014 Jun; 120(6):1313-20. PubMed ID: 24405075
[TBL] [Abstract][Full Text] [Related]
12. Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis.
Bohman LE; Koch M; Bailey RL; Alonso-Basanta M; Lee JY
World Neurosurg; 2014 Nov; 82(5):806-14. PubMed ID: 25009165
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients.
Wang L; Wu Z; Tian K; Wang K; Li D; Ma J; Jia G; Zhang L; Zhang J
J Neurosurg; 2017 Dec; 127(6):1257-1267. PubMed ID: 28059654
[TBL] [Abstract][Full Text] [Related]
14. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
[TBL] [Abstract][Full Text] [Related]
17. Analysis of clinical factors and PDGFR-β in predicting prognosis of patients with clival chordoma.
Zhai Y; Bai J; Wang S; Gao H; Li M; Li C; Gui S; Zhang Y
J Neurosurg; 2018 Dec; 129(6):1429-1437. PubMed ID: 29303447
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas.
Bai J; Zhai Y; Wang S; Gao H; Du J; Wang J; Li M; Li C; Gui S; Zhang C; Sun Y; Zhang Y
World Neurosurg; 2017 Mar; 99():282-287. PubMed ID: 27916725
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
[TBL] [Abstract][Full Text] [Related]
20. Disease outcomes for skull base and spinal chordomas: a single center experience.
Ahmed R; Sheybani A; Menezes AH; Buatti JM; Hitchon PW
Clin Neurol Neurosurg; 2015 Mar; 130():67-73. PubMed ID: 25590662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]